Overview: South African Thoracic Society 2019 COPD Guidelines (SATS Position Statement)

This guideline, published in 2019 by the South African Thoracic Society, outlines evidence-based recommendations tailored for the South African context PMC+5PMC+5jtd.amegroups.org+5.

Key Components of Management:

1. Diagnosis & Assessment
   • Spirometry is essential for confirming COPD (post-bronchodilator FEV₁/FVC < 0.70) PMC.
   • Symptom severity is assessed using tools like the mMRC dyspnoea scale or CAT score; exacerbation history (≥2 per year or hospitalization) is also captured ResearchGate+1.
2. Smoking Cessation & Prevention Strategies
   • Smoking remains the leading modifiable risk factor; cessation programs are central to halting progression.
   • Addressing additional risks like HIV, TB, biomass fuel exposure is highlighted Studocu+2PMC+2PMC.
3. Non‑Pharmacologic Interventions
   • Pulmonary Rehabilitation improves symptoms, physical function, and quality of life.
   • Vaccinations, including annual influenza and pneumococcal vaccines, reduce exacerbation rates PMCpubmed.ncbi.nlm.nih.gov+4irishhealthpro.com+4PMC+4.
   • For patients with chronic respiratory failure and resting hypoxaemia, long-term oxygen therapy (>15 hours/day) is indicated PMC.
4. Pharmacotherapy — Tailored by GOLD-Like Groupings:
   • GOLD Group A (mild symptoms, low exacerbation risk)
     — As-needed short‑acting bronchodilators (SABA or SAMA) PMCResearchGate+2PMC+2.
   • Group B (more symptomatic, low exacerbation risk)
     — Begin long‑acting bronchodilator therapy: choice of LAMA or LABA; consider dual-bronchodilator (LAMA + LABA) if symptoms persist PMC+4ResearchGate+4Studocu+4.
   • Group D (frequent exacerbations or severe symptoms)
     — Start with LAMA, escalate to LAMA + LABA; or LABA + ICS if eosinophils are elevated or frequent exacerbations. Referral for specialist evaluation if control remains poor ResearchGate.
     — Additional options at specialist level: roflumilast, macrolide antibiotics, or theophylline depending on clinical phenotype (e.g. chronic bronchitic, eosinophilic) ResearchGatejtd.amegroups.org.
5. Oral Corticosteroids and PDE‑4 Inhibitors
   • Oral corticosteroids are not recommended for long-term maintenance, but can be used short-term (≈5 days) during acute exacerbations jtd.amegroups.org.
   • Roflumilast (PDE‑4 inhibitor) may benefit patients with severe, frequent exacerbations and chronic bronchitis phenotype, but side effects (GI upset, weight loss, insomnia, depression) limit use jtd.amegroups.org.
6. Other Therapies
   • Routine use of mucolytics or mechanical airway clearance isn’t widely recommended unless excessive sputum is present; benefits are modest jtd.amegroups.org+1.
   • Alpha‑1 antitrypsin augmentation therapy is reserved for non-smoking patients with AAT deficiency and moderate FEV₁ impairment—but cost limits availability in South Africa jtd.amegroups.org.
7. Comorbidities, Specialist Therapies & Advanced Options
   • Management of co-existing conditions (especially cardiovascular disease, diabetes, osteoporosis) is integral to COPD care.
   • In advanced disease, evaluation for lung volume reduction surgery, lung transplantation, or long‑term domiciliary oxygen is advised PMC.

---

???? Quick Reference Table

COPD Group	Symptoms & Exacerbations	Recommended Therapy
GOLD A (mild)	mMRC <2, CAT <10, ≤1 exacerbation/year	PRN SABA or SAMA
GOLD B (symptomatic)	mMRC ≥2 or CAT >10, low exacerbation risk	LAMA or LABA; escalate to LAMA + LABA
GOLD D (high risk)	Frequent exacerbations or hospitalization	LAMA → LAMA + LABA ± ICS; specialist add-ons if needed

—

???? Additional Highlights for South African Practice

• Emphasis on cost-effectiveness: LAMA/LABA combos reduce exacerbations more than LABA/ICS and carry lower pneumonia risk, though cost may be limiting.
• Avoid long-term oral steroids and steroid trials for chronic use—they carry substantial side effects without reliable benefit.
• Local realities such as high burden of TB, HIV, and limited drug availability shape the practical guidance PMC+3ResearchGate+3PMC+3PMC.

---

✅ Summary

The SATS 2019 guideline offers a structured, local-context management framework for COPD emphasizing:

• Accurate diagnosis (spirometry) and symptom/exacerbation assessment
• Smoking cessation and vaccination
• Stepwise pharmacotherapy based on symptom burden and exacerbation risk
• Responsible use of ICS and PDE-4 inhibitors for selected patients
• Integration of rehabilitation, management of comorbidities, and consideration of advanced therapies when appropriate.

If you actually meant something else by “Neftaly,” feel free to clarify. Otherwise, I hope this helps you understand the up‑to-date South African approach.